$0.77
-0.03 (-3.43%)
HCWB News3 articles
HCW Biologics Rockets 122% as Traders Flock to Micro-Cap Biotech
HCW Biologics shares skyrocketed 122% to $2.35 on Wednesday as traders piled into the micro-cap biotech, fueled by a new stock offering and first-quarter revenue of $6.54 million from a licensing deal.
HCW Biologics Surges 262% on Trimmune Deal and Profit, Nasdaq Risk Looms
HCW Biologics shares jumped 262% after a licensing deal with Beijing Trimmune Biotech fueled a Q1 profit. The company still faces Nasdaq delisting risks and will seek shareholder approval for a reverse stock split.
HCW Biologics Posts Profit on China Deal, Faces Nasdaq and Pipeline Tests
HCW Biologics posted a $3.47M profit in Q1 2026, driven by a licensing deal with Trimmune Biotech. The company still trades below Nasdaq's $1 minimum and awaits early human data for its lead alopecia drug.